Lung Cancer clinical trials in New Mexico

12 actively recruiting lung cancer trials at 4 sites across New Mexico.

Data from ClinicalTrials.gov · last refreshed 2026-10-12

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04267848

Sites in New Mexico:

Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico
University of New Mexico Cancer Center — Albuquerque, New Mexico
Presbyterian Kaseman Hospital — Albuquerque, New Mexico
Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer

NCT ID: NCT07222566

Sites in New Mexico:

University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
CHRISTUS St. Vincent Regional Cancer Center — Santa Fe, New Mexico

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche

NCT ID: NCT06793215

Sites in New Mexico:

San Juan Oncology Associates — Farmington, New Mexico

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb

NCT ID: NCT06561386

Sites in New Mexico:

Local Institution - 0381 — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca

NCT ID: NCT07291037

Sites in New Mexico:

Research Site — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Sponsor: Eikon Therapeutics

NCT ID: NCT07365319

Sites in New Mexico:

University of New Mexico - Comprehensive Cancer Center — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homol…

Sponsor: Hoffmann-La Roche

NCT ID: NCT07541170

Sites in New Mexico:

San Juan Oncology Associates — Farmington, New Mexico

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc

NCT ID: NCT07002034

Sites in New Mexico:

University of New Mexico, School of Medicine — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in New Mexico:

Massive Bio SYNERGY-AI site — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Recruiting Industry

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at disconti…

Sponsor: N-Power Medicine

NCT ID: NCT07028489

Sites in New Mexico:

New Mexico Oncology Hematology Consultants — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Recruiting Industry

BostonGene and Exigent Genomic INsight Study

The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, asse…

Sponsor: BostonGene

NCT ID: NCT06272864

Sites in New Mexico:

New Mexico Cancer Center — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Recruiting Industry

Collection of Sputum and Labeling for Lung Cancer

The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy…

Sponsor: bioAffinity Technologies Inc.

NCT ID: NCT03457415

Sites in New Mexico:

Radiology Associates of Albuquerque — Albuquerque, New Mexico

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12